Please login to the form below

Not currently logged in

Pfizer and Astellas co-promote Caduet

Pfizer Japan and Astellas have agreed to co-promote a combination hypertension and hypercholesterolemia drug in Japan

The treatment, Caduet Combination Tablets, is an oral combination of Pfizer's hypertension treatment, Norvasc (amlodipine besylate) and hypercholesterolemia drug, Lipitor (atorvastatin calcium). The single tablet combination is expected to improve patient adherence.

Under the terms of the agreement (which lasts until July 2016), Pfizer will manufacture the combination treatment and be responsible for sales, while both companies will promote it.

The companies have worked together previously and co-promote Lipitor. Caduet Combination Tablets are approved in more than 70 countries/areas and will be available in Japan once listed on Japan's National Health Insurance drug price list.

26th August 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Beyond the event
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...